Find a Clinical Trial

Showing 41 - 46 of 46 Trials

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

Principal Investigator:

Dawn L Hershman, MD

Contact Number:

212-342-5162

NCT Number:

NCT04960787

Population:

Adult

Phase:

NA

Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage the financial aspects of cancer care? A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health...
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT02922764

Population:

Adult

Phase:

I

The main purpose of this study is learn about the the safety and side effects of the study drug, RGX-104. RGX-104 is an experimental drug. This means that RGX-104 is not approved by the Food and Drug Administration (FDA). This is the first time RGX-104 will be given to humans. Are you Eligible? (Inclusion Criteria) Do you have a confirmed solid tumor? Have you had treatment for your disease before? Or is there not a standard treatment available for your disease? Does your cancer continue to grow? Can your cancer not be removed by surgery? Are you 18 years of age or older?
Phase 1/2 Study of RTX-240 as a Monotherapy and in combination with Pembrolizumab (RTX-240-01)

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT04372706

Population:

Adult

Phase:

I/II

The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectivnes of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating your cancer, how much needs to be given for it to work and how often it should be given. The study drug will be administered through IV and the time frame for the study will vary based on the response to treatment. The study drug is made of...
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”

Principal Investigator:

Grace A. Hillyer

Contact Number:

(212) 342-5162

NCT Number:

NCT03808818

Population:

Adult

Phase:

II

The purpose of this study is to compare two treatment programs for smoking cessation. Providing treatment medication at no cost to participants and providing additional counseling sessions could help more participants quit smoking and stay smoke free. There will be about 308 people taking part in this study. Are you Eligible? (Inclusion Criteria) Are you 18 year of age or older? Have you been diagnosed with cancer within the past 4 months? Have you had at least one puff of a cigarette in the past 30 days?
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Principal Investigator:

Richard D Carvajal, MD

Contact Number:

212-342-5162

NCT Number:

NCT05279300

Population:

Adult

Phase:

I

This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any condition. It is only available in clinical studies such as this one. To date, it has only been tested in animal studies. This is the first time that the study drug will be given to humans. Are you Eligible? (Inclusion Criteria) Are you at least...
Evaluation of a Pharmacist-Led Video Consultation to Identify Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

Principal Investigator:

Dawn L Hershman, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

NA

- Are you 18 years old or older? - Do you have access to a smartphone, tablet, or computer to facilitate a video visit, or be willing to come into the hospital to borrow a tablet for the visit? - Did you receive a prescription for a new oral anti-cancer drug within 4 weeks taking part of this study? Are you Eligible? (Inclusion Criteria) Are you 18 years old or older? Do you have access to a smartphone, tablet, or computer to facilitate a video visit, or be willing to come into the hospital to borrow a tablet for the visit? Did you receive a prescription for a new oral anti-cancer drug within...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Pages